These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16574701)

  • 1. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.
    Hofbauer LC; Schoppet M; Christ M; Teichmann J; Lange U
    Rheumatology (Oxford); 2006 Oct; 45(10):1218-22. PubMed ID: 16574701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation.
    Grisar J; Bernecker PM; Aringer M; Redlich K; Sedlak M; Wolozcszuk W; Spitzauer S; Grampp S; Kainberger F; Ebner W; Smolen JS; Pietschmann P
    J Rheumatol; 2002 Jul; 29(7):1430-6. PubMed ID: 12136902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men.
    Gibellini D; Borderi M; De Crignis E; Cicola R; Vescini F; Caudarella R; Chiodo F; Re MC
    J Med Virol; 2007 Oct; 79(10):1446-54. PubMed ID: 17705184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
    Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
    HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?
    Castellino G; Corallini F; Trotta F; Secchiero P
    Ann Rheum Dis; 2008 Aug; 67(8):1196-7. PubMed ID: 18621972
    [No Abstract]   [Full Text] [Related]  

  • 15. The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis.
    Morabito N; Russo GT; Gaudio A; Lasco A; Catalano A; Morini E; Franchina F; Maisano D; La Rosa M; Plota M; Crifò A; Meo A; Frisina N
    Bone; 2007 Jun; 40(6):1588-94. PubMed ID: 17412659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies.
    Castellino G; Corallini F; Trotta F; Secchiero P
    Lupus; 2007; 16(7):479-82. PubMed ID: 17670845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
    Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
    Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.
    Oh KW; Rhee EJ; Lee WY; Kim SW; Oh ES; Baek KH; Kang MI; Choi MG; Yoo HJ; Park SW
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):244-9. PubMed ID: 15272921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
    Mangiafico RA; Malaponte G; Pennisi P; Li Volti G; Trovato G; Mangiafico M; Bevelacqua Y; Mazza F; Fiore CE
    J Intern Med; 2007 Jun; 261(6):587-96. PubMed ID: 17547714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.